UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

The New England journal of medicine, 2018-11, Vol.379 (18), p.1711-1721

2018

Volltextzugriff (PDF)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Frontiers in oncology, 2020-01, Vol.9, p.1380-1380

2020

Volltextzugriff (PDF)

Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

Clinical cancer research, 2009-05, Vol.15 (10), p.3251-3255

2009

Volltextzugriff (PDF)

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3230-3237

2007

Volltextzugriff (PDF)

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3133-3140

2009

Volltextzugriff (PDF)

Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice

Cancer research (Chicago, Ill.), 2008-03, Vol.68 (6), p.2024-2032

2008

Volltextzugriff (PDF)

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Volltextzugriff (PDF)

Heat shock proteins: a potential anticancer target

Current drug targets, 2011-12, Vol.12 (14), p.2001-2008

2011

Volltextzugriff (PDF)

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Clinical cancer research, 2006-01, Vol.12 (1), p.144-151

2006

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1885-1893

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.570-576

2008

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.563-569

2008

Volltextzugriff (PDF)

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Journal of clinical oncology, 2019-04, Vol.37 (12), p.946-953

2019

Volltextzugriff (PDF)

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Cancer chemotherapy and pharmacology, 2015-03, Vol.75 (3), p.495-503

2015

Volltextzugriff (PDF)

Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials

Cancer chemotherapy and pharmacology, 2008-04, Vol.61 (4), p.535-548

2008

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Journal of clinical oncology, 2006-02, Vol.24 (4), p.552-562

2006

Volltextzugriff (PDF)

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

Clinical cancer research, 2007-08, Vol.13 (16), p.4832-4839

2007

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2003-01, Vol.21 (1), p.148-157

2003

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Cancer epidemiology, biomarkers & prevention, 2003-11, Vol.12 (11), p.1213-1221

2003

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Clinical cancer research, 2007-05, Vol.13 (9), p.2675-2683

2007

Volltextzugriff (PDF)

Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study

Clinical cancer research, 2007-06, Vol.13 (12), p.3660-3666

2007

Volltextzugriff (PDF)

Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study

Journal of clinical oncology, 2003-07, Vol.21 (14), p.2664-2672

2003

Volltextzugriff (PDF)

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients

Clinical cancer research, 2009-01, Vol.15 (1), p.346-354

2009

Volltextzugriff (PDF)

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

Clinical cancer research, 2005-11, Vol.11 (21), p.7866-7871

2005

Volltextzugriff (PDF)

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Clinical cancer research, 2010-06, Vol.16 (11), p.3044-3056

2010

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Humans
(87)
Science & Technology
(82)
Life Sciences & Biomedicine
(81)
Oncology
(69)
Biological And Medical Sciences
(64)
Medical Sciences
(61)
Female
(55)
Male
(55)
Pharmacology. Drug Treatments
(52)
Middle Aged
(50)
Adult
(48)
Antineoplastic Agents
(47)
Neoplasms - Drug Therapy
(46)
Aged
(44)
Chemotherapy
(27)
Dose-Response Relationship, Drug
(22)
Aged, 80 And Over
(21)
Pharmacology & Pharmacy
(19)
Antineoplastic Agents - Pharmacokinetics
(18)
Infusions, Intravenous
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Heat shock proteins: a potential anticancer target

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies

Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study

Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Aktive Filter

Suchergebnisse filtern